117 related articles for article (PubMed ID: 26563651)
1. Targeting anti-apoptotic Bcl2 proteins with scyllatoxin-based BH3 domain mimetics.
Harris MM; Coon Z; Alqaeisoom N; Swords B; Holub JM
Org Biomol Chem; 2016 Jan; 14(2):440-446. PubMed ID: 26563651
[TBL] [Abstract][Full Text] [Related]
2. Role of single disulfide linkages in the folding and activity of scyllatoxin-based BH3 domain mimetics.
Arachchige D; Margaret Harris M; Coon Z; Carlsen J; Holub JM
J Pept Sci; 2017 May; 23(5):367-373. PubMed ID: 28326661
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Biological Activity of Scyllatoxin-Based BH3 Domain Mimetics Containing Two Disulfide Linkages.
Arachchige D; Holub JM
Protein J; 2018 Oct; 37(5):428-443. PubMed ID: 30128635
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of Scyllatoxin-Based BH3 Domain Mimetics with Diverse Patterns of Native Disulfide Bonds.
Vince MJK; Holub JM
Curr Protoc; 2022 Aug; 2(8):e526. PubMed ID: 35994574
[TBL] [Abstract][Full Text] [Related]
5. Pro-apoptotic activity of BH3-only proteins and BH3 mimetics: from theory to potential cancer therapy.
Hartman ML; Czyz M
Anticancer Agents Med Chem; 2012 Oct; 12(8):966-81. PubMed ID: 22263800
[TBL] [Abstract][Full Text] [Related]
6. Design of protein-protein interaction inhibitors based on protein epitope mimetics.
Robinson JA
Chembiochem; 2009 Apr; 10(6):971-3. PubMed ID: 19266524
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of conformationally constrained benzoylureas as BH3-mimetics.
Brady RM; Hatzis E; Connor T; Street IP; Baell JB; Lessene G
Org Biomol Chem; 2012 Jul; 10(27):5230-7. PubMed ID: 22648632
[TBL] [Abstract][Full Text] [Related]
8. Bcl2L12 with a BH3-like domain in regulating apoptosis and TMZ-induced autophagy: a prospective combination of ABT-737 and TMZ for treating glioma.
Yang MC; Loh JK; Li YY; Huang WS; Chou CH; Cheng JT; Wang YT; Lieu AS; Howng SL; Hong YR; Chou AK
Int J Oncol; 2015 Mar; 46(3):1304-16. PubMed ID: 25586056
[TBL] [Abstract][Full Text] [Related]
9. Design and application of an alpha-helix-mimetic scaffold based on an oligoamide-foldamer strategy: antagonism of the Bak BH3/Bcl-xL complex.
Ernst JT; Becerril J; Park HS; Yin H; Hamilton AD
Angew Chem Int Ed Engl; 2003 Feb; 42(5):535-9. PubMed ID: 12569483
[No Abstract] [Full Text] [Related]
10. BH3 Mimetics in AML Therapy: Death and Beyond?
Cerella C; Dicato M; Diederich M
Trends Pharmacol Sci; 2020 Nov; 41(11):793-814. PubMed ID: 33032835
[TBL] [Abstract][Full Text] [Related]
11. Terephthalamide derivatives as mimetics of helical peptides: disruption of the Bcl-x(L)/Bak interaction.
Yin H; Lee GI; Sedey KA; Rodriguez JM; Wang HG; Sebti SM; Hamilton AD
J Am Chem Soc; 2005 Apr; 127(15):5463-8. PubMed ID: 15826183
[TBL] [Abstract][Full Text] [Related]
12. Terphenyl-Based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL.
Yin H; Lee GI; Sedey KA; Kutzki O; Park HS; Orner BP; Ernst JT; Wang HG; Sebti SM; Hamilton AD
J Am Chem Soc; 2005 Jul; 127(29):10191-6. PubMed ID: 16028929
[TBL] [Abstract][Full Text] [Related]
13. Development of Noxa-like BH3 mimetics for apoptosis-based therapeutic strategy in chronic lymphocytic leukemia.
Billard C
Mol Cancer Res; 2012 Jun; 10(6):673-6. PubMed ID: 22466256
[TBL] [Abstract][Full Text] [Related]
14. Structural insights into BCL2 pro-survival protein interactions with the key autophagy regulator BECN1 following phosphorylation by STK4/MST1.
Lee EF; Smith NA; Soares da Costa TP; Meftahi N; Yao S; Harris TJ; Tran S; Pettikiriarachchi A; Perugini MA; Keizer DW; Evangelista M; Smith BJ; Fairlie WD
Autophagy; 2019 May; 15(5):785-795. PubMed ID: 30626284
[TBL] [Abstract][Full Text] [Related]
15. Bcl-2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside.
Vela L; Marzo I
Curr Opin Pharmacol; 2015 Aug; 23():74-81. PubMed ID: 26079328
[TBL] [Abstract][Full Text] [Related]
16. New dimension in therapeutic targeting of BCL-2 family proteins.
Besbes S; Mirshahi M; Pocard M; Billard C
Oncotarget; 2015 May; 6(15):12862-71. PubMed ID: 25970783
[TBL] [Abstract][Full Text] [Related]
17. Two-face, two-turn α-helix mimetics based on a cross-acridine scaffold: analogues of the Bim BH3 domain.
Li X; Wang Z; Feng Y; Song T; Su P; Chen C; Chai G; Yang Y; Zhang Z
Chembiochem; 2014 Jun; 15(9):1280-5. PubMed ID: 24838655
[TBL] [Abstract][Full Text] [Related]
18. Piercing the armor of hepatobiliary cancer: Bcl-2 homology domain 3 (BH3) mimetics and cell death.
Mott JL; Gores GJ
Hepatology; 2007 Sep; 46(3):906-11. PubMed ID: 17654739
[No Abstract] [Full Text] [Related]
19. Small-molecule inhibitors of Bcl-2 family proteins are able to induce tumor regression in a mouse model of pre-B-cell acute lymphocytic lymphoma.
Turner BC; Eves T; Refaeli Y
DNA Cell Biol; 2008 Mar; 27(3):133-42. PubMed ID: 18163880
[TBL] [Abstract][Full Text] [Related]
20. Rational design of new class of BH3-mimetics as inhibitors of the Bcl-xL protein.
Pinto M; Orzaez Mdel M; Delgado-Soler L; Perez JJ; Rubio-Martinez J
J Chem Inf Model; 2011 Jun; 51(6):1249-58. PubMed ID: 21528891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
